GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.
Topical androgen receptor antagonists may not be necessary if 5-ARinhibitors like finasteride or dutasteride effectively reduce DHT levels. Combining a 5-ARinhibitor with a topical androgen antagonist could potentially enhance treatment, but oral use of androgen antagonists is too risky due to severe side effects.
The conversation is about which blood markers to test before starting a 5-ARinhibitor for hair loss. The user mentions already testing Total T, Free T, SHBG, Estradiol, Haematocrit, Red blood cell count, and White cell count, and asks if DHT or additional markers are needed.
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-ARinhibitors in reducing hair loss.
The user experienced male pattern baldness starting at 18, tried finasteride with no success, and switched to dutasteride, which halted hair loss. Minoxidil had no effect for them, while their brother, who didn't use ARinhibitors, maintained a juvenile hairline and successfully grew a beard with minoxidil, highlighting the unpredictable nature of genetics in hair loss and treatment response.